- Home
- LILA vs SLBT Comparison
LILA vs SLBT Comparison
Compare LILA & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LILA | SLBT |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Bermuda | Taiwan |
| Employees | 9000 | 20 |
| Industry | Cable & Other Pay Television Services | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LILA | SLBT |
|---|---|---|
| Price | $8.38 | $2.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 578.3K | 87.6K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.77 | $2.54 |
| 52 Week High | $9.04 | $6.25 |
Technical Indicators
Market Signals| Indicator | LILA | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 39.96 |
| Support Level | $7.10 | $2.54 |
| Resistance Level | $8.81 | $5.10 |
| Average True Range (ATR) | 0.30 | 0.38 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 81.57 | 14.15 |
Price Performance
Historical ComparisonAbout LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.